BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23760812)

  • 1. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
    Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and disposition of imatinib mesylate in healthy volunteers.
    Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
    Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers.
    Bello CL; LaBadie RR; Ni G; Boutros T; McCormick C; Ndongo MN
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):991-7. PubMed ID: 22147075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers.
    Blight AR; Henney HR
    Clin Ther; 2009 Feb; 31(2):328-35. PubMed ID: 19302905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
    Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
    J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
    Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
    Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.
    Stopfer P; Marzin K; Narjes H; Gansser D; Shahidi M; Uttereuther-Fischer M; Ebner T
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1051-61. PubMed ID: 22200729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
    Darwish M; Nunez R; Youakim JM; Robertson P
    Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.
    Sturm S; Seiberling M; Weick I; Paehler A; Funk C; Ruf T
    Clin Ther; 2012 Feb; 34(2):420-9. PubMed ID: 22244809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib.
    Giri N; Masters JC; Plotka A; Liang Y; Boutros T; Pardo P; O'Connell J; Bello C
    Invest New Drugs; 2015 Aug; 33(4):931-41. PubMed ID: 26048096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.
    Paulson SK; Hribar JD; Liu NW; Hajdu E; Bible RH; Piergies A; Karim A
    Drug Metab Dispos; 2000 Mar; 28(3):308-14. PubMed ID: 10681375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6.
    Chen X; Jiang J; Giri N; Hu P
    Xenobiotica; 2018 May; 48(5):459-466. PubMed ID: 28648122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.
    Slatter JG; Stalker DJ; Feenstra KL; Welshman IR; Bruss JB; Sams JP; Johnson MG; Sanders PE; Hauer MJ; Fagerness PE; Stryd RP; Peng GW; Shobe EM
    Drug Metab Dispos; 2001 Aug; 29(8):1136-45. PubMed ID: 11454733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate.
    Terlinden R; Uragg H; Göhler K; Kneip C
    Contraception; 2006 Sep; 74(3):239-44. PubMed ID: 16904418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the absorption, metabolism and excretion of [¹⁴C]pasireotide in healthy volunteers using accelerator mass spectrometry.
    Lin TH; Hu K; Flarakos J; Sharr-McMahon M; Mangold JB; He H; Wang Y
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):181-8. PubMed ID: 23680921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
    Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass balance, metabolic disposition, and pharmacokinetics of [
    Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.